Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood

Xenotransplantation

Volumn 24, Issue 1, 2017, Pages

  Abicht, Jan Michael ^a   Kourtzelis, Ioannis ^b   Reichart, Bruno ^c   Koutsogiannaki, Sophia ^d   Primikyri, Alexandra ^d   Lambris, John D ^d   Chavakis, Triantafyllos ^b   Holdt, Lesca ^a   Kind, Alexander ^e   Guethoff, Sonja ^a   Mayr, Tanja ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

complement; compstatin; ex vivo; heart; xenotransplantation

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; CP40; LACTATE DEHYDROGENASE; LACTIC ACID; UNCLASSIFIED DRUG; 1-(ETHAN-1-OL)-2-METHYL-3-HYDROXYPYRIDIN-4-ONE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD SAMPLING; COLD ISCHEMIA; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EDEMA; EX VIVO STUDY; HEART FUNCTION; HEART INDEX; HEART PERFUSION; HEART TRANSPLANTATION; HEMODYNAMICS; HISTOLOGY; HUMAN; HUMAN EXPERIMENT; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; NORMAL HUMAN; PHARMACOLOGICAL BLOCKING; PIG; THROMBOELASTOGRAPHY; WILD TYPE; ANIMAL; CARDIAC MUSCLE; GRAFT REJECTION; HEART; IMMUNOLOGY; METABOLISM; PROCEDURES; XENOGRAFT;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C3; GRAFT REJECTION; HEART; HEART TRANSPLANTATION; HUMANS; MYOCARDIUM; PYRIDONES; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84989271283     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12262     Document Type: Article

References (36)

1. Cowan PJ, D'Apice AJ. Complement activation and coagulation in xenotransplantation. Immunol Cell Biol. 2009;87:203–208.
2. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
3. Pierson RN III, Dorling A, Ayares D, et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation. 2009;16:263–280.
4. Ekser B, Ezzelarab M, Hara H, et al. Clinical xenotransplantation: the next medical revolution? Lancet. 2012;379:672–683.
5. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996;157:884–891.
6. Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol. 2008;632:273–292.
7. Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123:2094–2101.
8. Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45:423–440.
9. Reis ES, Deangelis RA, Chen H, et al. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology. 2015;220:476–482.
10. Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–1010.
11. Fiane AE, Mollnes TE, Videm V, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999;6:52–65.
12. Kourtzelis I, Ferreira A, Mitroulis I, et al. Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. Horm Metab Res. 2015;47:36–42.
13. Bretschneider HJ, Hubner G, Knoll D, et al. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Cardiovasc Surg (Torino). 1975;16:241–260.
14. Holscher M, Groenewoud AF. Current status of the HTK solution of Bretschneider in organ preservation. Transplant Proc. 1991;23:2334–2337.
15. Qu H, Ricklin D, Bai H, et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology. 2013;218:496–505.
16. Soerman A, Zhang L, Ding Z, et al. How antibodies use complement to regulate antibody responses. Mol Immunol. 2014;61:79–88.
17. Atkinson JP, Farries T. Separation of self from non-self in the complement system. Immunol Today. 1987;8:212–215.
18. Calne RY. Organ transplantation between widely disparate species. Transplant Proc. 1970;2:550–556.
19. Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. The role of complement in biomaterial-induced inflammation. Mol Immunol. 2007;44:82–94.
20. Ekdahl KN, Teramura Y, Asif S, et al. Thromboinflammation in therapeutic medicine. In: Lambris JD, Ekdahl KN, Ricklin D, Nilsson B, eds. Immune Responses to Biosurfaces. Cham: Springer International Switzerland Publishing; 2015:3–18.
21. Byrne GW, Mcgregor CG, Breimer ME. Recent investigations into pig antigen and anti-pig antibody expression. Int J Surg. 2015;23:223–228.
22. Petersen B, Ramackers W, Tiede A, et al. Pigs transgenic for human thrombomodulin have elevated production of activated protein C. Xenotransplantation. 2009;16:486–495.
23. Wuensch A, Baehr A, Bongoni AK, et al. Regulatory sequences of the porcine THBD gene facilitate endothelial-specific expression of bioactive human thrombomodulin in single- and multitransgenic pigs. Transplantation. 2014;97:138–147.
24. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation. 1988;46:825–830.
25. Vogel CW, Fritzinger DC, Hew BE, Thorne M, Bammert H. Recombinant cobra venom factor. Mol Immunol. 2004;41:191–199.
26. Mohiuddin MM, Singh AK, Corcoran PC, et al. One-year heterotopic cardiac xenograft survival in a pig to baboon model. Am J Transplant. 2014;14:488–489.
27. Mohiuddin MM, Singh AK, Corcoran PC, et al. Genetically engineered pigs and target-specific immunomodulation provide significant graft survival and hope for clinical cardiac xenotransplantation. J Thorac Cardiovasc Surg. 2014;148:1106–1113. discussion 1113-1104.
28. Cooper DK, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases. J Heart Lung Transplant. 2000;19:1125–1165.
29. Schmoeckel M, Bhatti FN, Zaidi A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation. 1998;65:1570–1577.
30. Vial CM, Ostlie DJ, Bhatti FN, et al. Life supporting function for over one month of a transgenic porcine heart in a baboon. J Heart Lung Transplant. 2000;19:224–229.
31. Brandl U, Michel S, Erhardt M, et al. Administration of GAS914 in an orthotopic pig-to-baboon heart transplantation model. Xenotransplantation. 2005;12:134–141.
32. Brenner P, Schmoeckel M, Wimmer C, et al. Mean xenograft survival of 14.6 days in a small group of hDAF-transgenic pig hearts transplanted orthotopically into baboons. Transplant Proc. 2005;37:472–476.
33. Byrne GW, McGregor CG. Cardiac xenotransplantation: progress and challenges. Curr Opin Organ Transplant. 2012;17:148–154.
34. Abicht J, Mayr T, Reichart B, et al. Preclinical heterotopic intrathoracic heart xenotransplantation: a possibly useful clinical technique. Xenotransplantation. 2015;22:427–442.
35. Thomas TC, Rollins SA, Rother RP, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol. 1996;33:1389–1401.
36. Kelly RJ, Hochsmann B, Szer J, et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2015;373:1032–1039.